1Lami MC,Hadjadj S,Guillet G.Hair loss in three patients with acromegaly treated with octreotide[].Br J Dermatol.2003
2Fueger BJ,Hamilton G,Raderer M,et al.Effects of chemotherapeutic agents on expres-sion of somatostatin receptors in pancreatic tumor cells[].The Journal of Nuclear Medicine.2001
3Kouroumalis EA,Skordilis P,Thermos K,et al.Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study[].Gut.1998
4Flogstad AK,Halse J,Haldorsen T,et al.Sandostatin LAR in acromegalic patients: a dose-range study[].The Journal of Clinical Endocrinology.1995
5Lancranjan l,Bruns C,Grass P,et al.Sandostatin LAR: a promising therapeutic tool in the management of acromgalic patients[].Metabolism.
6Bousquet C,Puente E,Buscail L,et al.Antiproliferative effect of somatostatin analogs[].Chemotherapy.
7Pollak MN,Schally AV.Mechanisms of antineo-plastic action of somatostatin analogs[].Proceedings of the Society for Experimental Biology and Medicine.1998
8Raderer M,Hejna M,Kurtaran A,et al.Suc-cessful treatment of an advanced hepatocellular carcinoma with long-acting somatostatin analog lanreotide[].The American journal of Gastroenterology.1999
9Dimitroulopoulos D,Xinopoulos D,Tsamakidis K,et al.The role of sandostatin LAR in treating patients with advanced hepatocellular cancer[].Hepato Gastroenterology.2002
10Grsaa P,Marbach P,Bruns C,et al.Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacody-namic relationships[].Metabolicm.
